Ceritinib/Ceritinib (Zanda) belongs to which generation of drugs and analysis of its clinical significance

Ceritinib (Ceritinib, also known as ceritinib) is an oral small molecule targeted drug and a second-generation ALK (anaplastic lymphoma kinase) inhibitor. It was originally developed to overcome the resistance problem in some patients with the first-generation ALK inhibitor crizotinib. Compared with crizotinib, ceritinib has stronger selectivity and inhibitory activity and can act on a variety of ALK mutation sites, so it is of great significance in clinical treatment.

In terms of indications, ceritinib is mainly used to treat ALK positive non-small cell lung cancer (NSCLC). Such patients usually carry ALK gene rearrangements. Traditional chemotherapy has limited effect, but targeted drugs can significantly improve the prognosis. Clinical trials have confirmed that ceritinib has shown good efficacy in both first-line treatment and second-line treatment after failure of crizotinib treatment, can prolong progression-free survival (PFS), and can also achieve better disease control in some patients with drug-resistant mutations.

It is worth noting that the efficacy of ceritinib is more prominent in patients with central nervous system (CNS) metastasis. Since patients with non-small cell lung cancer often develop brain metastases, crizotinib has limited penetration of the blood-brain barrier, while ceritinib can more effectively control intracranial lesions and improve the overall treatment effect. This feature greatly expands its application value in complex clinical situations.

In general, as a second-generation ALK inhibitor, the launch of ceritinib has filled the treatment gap after resistance to first-generation drugs, and has gradually shown its advantages in first-line treatment. It not only improves the survival benefit of patients, but also promotes the treatment of ALK positive non-small cell lung cancer into a new stage of precision and individualization. In the future, with the emergence of more new-generation ALK inhibitors, ceritinib will still maintain important clinical significance in specific populations and types of drug-resistant mutations.

Reference materials:https://www.drugs.com/